The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?

High sustained virologic response (SVR) rates have been observed after 6 weeks of anti-HCV treatment using sofosbuvir, ledipasvir and a non-nucleoside polymerase-inhibitor (GS-9669) or a protease-inhibitor (GS-9451) and after 12 weeks with sofosbuvir + ledipasvir. Here we analyze the viral kinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi Huyen Tram, Guedj, Jérémie, Uprichard, Susan L., Kohli, Anita, Kottilil, Shyam, Perelson, Alan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579268/
https://www.ncbi.nlm.nih.gov/pubmed/28860456
http://dx.doi.org/10.1038/s41598-017-09776-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579268/
https://www.ncbi.nlm.nih.gov/pubmed/28860456
http://dx.doi.org/10.1038/s41598-017-09776-z

Ejemplares similares